Wave Life Sciences Ltd.
NASDAQ•WVE
CEO: Dr. Paul B. Bolno M.B.A., M.D.
セクター: Healthcare
業種: Biotechnology
上場日: 2015-11-11
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
連絡先情報
Marina One East Tower, 7 Straits View No.12-00, Singapore, 018936, Singapore
65-6236-3388
時価総額
$2.35B
PER (TTM)
-11.0
17.2
配当利回り
--
52週高値
$21.73
52週安値
$5.28
52週レンジ
順位46Top 59.5%
3.5
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 3.5 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q4 2025 データ
売上高
$17.25M+0.00%
直近4四半期の推移
EPS
-$0.30+0.00%
直近4四半期の推移
フリーCF
-$32.11M+0.00%
直近4四半期の推移
2025 Annual 決算ハイライト
主なハイライト
WVE-007 Obesity Trial Data WVE-007 showed 9.4% visceral fat reduction at three months in Phase 1 SAD cohort, supporting durable dosing.
AATD Program Regulatory Acceleration Accelerated regulatory engagement for WVE-006; positive data from RestorAATion-2 study cohorts announced September 2025.
HD Program Shows Clinical Benefit SELECT-HD trial showed potent, durable allele-selective mHTT reduction up to 46% in CSF, slowing atrophy.
Strong Cash Position Maintained Cash and equivalents totaled $602.1 M as of December 31, 2025, funding operations for at least twelve months.
リスク要因
Continued Operating Losses Expected Net loss reached $(204.4) M in 2025; expects significant operating losses for foreseeable future, accumulating deficit.
Substantial Additional Funding Required Requires substantial future funding to complete development, regulatory approvals, and commercialization efforts.
Reliance on Third-Party Manufacturing Relies on limited third parties for supply and manufacturing; failures could delay clinical timelines materially and increase costs.
Intellectual Property Enforcement Risk Patent landscape evolving; litigation risk exists protecting proprietary rights and ensuring freedom to operate globally.
見通し
WVE-007 Phase 2a Planning Planning underway to initiate WVE-007 Phase 2a multidose trial in first half of 2026 for obesity indication.
WVE-006 Regulatory Feedback Expected Expect regulatory feedback mid-2026 regarding potential accelerated approval pathway for WVE-006 AATD treatment.
WVE-008 Application Filing Expect to file clinical trial application for WVE-008 (PNPLA3 I148M liver disease) during 2026.
New Clinical Trials Initiated Expect initiation of new clinical trials evaluating WVE-007 as incretin add-on and post-incretin maintenance in 2026.
同業比較
売上高 (TTM)
$172.35M
$90.49M
$67.67M
粗利益率 (最新四半期)
102.3%
100.0%
99.0%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| TERN | $4.19B | -45.1 | -30.0% | 0.3% |
| SYRE | $2.65B | -98.0 | -29.4% | 0.0% |
| WVE | $2.35B | -11.0 | -85.0% | 2.8% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
23.4%
高成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要
深度リサーチ
次回決算:2026年5月6日
EPS:-
|売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書 | 直近12ヶ月 |
|---|
データなし